Leerink Partnrs Has Strong Estimate for CGEM FY2025 Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Analysts at Leerink Partnrs upped their FY2025 earnings estimates for Cullinan Therapeutics in a report issued on Monday, November 18th. Leerink Partnrs analyst A. Berens now forecasts that the company will post earnings per share of ($4.11) for the year, up from their prior estimate of ($4.16). The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics’ FY2026 earnings at ($3.06) EPS and FY2027 earnings at ($0.06) EPS.

Several other equities research analysts have also weighed in on CGEM. HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Cullinan Therapeutics in a report on Wednesday, October 16th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Cullinan Therapeutics in a research report on Wednesday, September 18th. Finally, UBS Group initiated coverage on shares of Cullinan Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $30.00 price target on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $31.67.

Cullinan Therapeutics Trading Down 4.0 %

Shares of NASDAQ CGEM opened at $12.58 on Wednesday. The firm has a market cap of $732.51 million, a price-to-earnings ratio of -4.43 and a beta of -0.12. The stock has a fifty day simple moving average of $16.24 and a two-hundred day simple moving average of $18.54. Cullinan Therapeutics has a 1-year low of $7.64 and a 1-year high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM) last released its earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.09.

Hedge Funds Weigh In On Cullinan Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its position in shares of Cullinan Therapeutics by 31.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,599 shares of the company’s stock valued at $44,000 after acquiring an additional 615 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Cullinan Therapeutics by 3.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 22,842 shares of the company’s stock worth $390,000 after buying an additional 820 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Cullinan Therapeutics by 39.4% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 17,481 shares of the company’s stock valued at $305,000 after buying an additional 4,941 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Cullinan Therapeutics by 757.2% during the 2nd quarter. SG Americas Securities LLC now owns 85,172 shares of the company’s stock worth $1,485,000 after acquiring an additional 75,236 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in Cullinan Therapeutics in the second quarter worth $1,992,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $15.64, for a total value of $125,120.00. Following the transaction, the insider now owns 107,942 shares of the company’s stock, valued at approximately $1,688,212.88. This represents a 6.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 6.07% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.